The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

The present invention relates to a novel feline paramyxovirus. The paramyxovirus of the present invention is a (-)ssRNA virus and has in one aspect a genome which is complementary to the nucleic acid according to SEQ ID NO:1 or SEQ ID NO:8. The invention further relates to corresponding nucleic acids and polypeptides, antibodies and vaccines. Further, the invention relates to medical uses and diagnostic methods concerning the paramyxovirus of the invention.

Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

An embodiment provides a method for identifying Covid-19 in a body fluid of a patient, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source; and returning the body fluid to the patient. Other aspects are described and claimed.

The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

A testing system and test cartridge for analyzing a sample of water from a water source for specific analyte levels. The test cartridge including a membrane filter that captures a target analyte while allowing a labelled conjugate to permeate through the membrane. The conjugate includes an analyte-specific labelled binding reagent to bind with the target analyte for optical detection. The direct membrane interrogation (i.e., on-filter detection), determines analyte levels without elution of the analyte from a filter thereby improving analyte recovering and assay sensitivity.

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

A system for diagnosing COVID-19 infection. The system includes a biosensor, an electrochemical stimulator-analyzer, and a processing unit. The biosensor is configured to be put in contact with a blood serum sample of a person suspected to be infected of COVID-19 virus. The processing unit is configured to apply an AC potential amplitude to the biosensor while sweeping a frequency range utilizing the electrochemical stimulator-analyzer, recording an electrochemical impedance spectroscopy (EIS) associated with the blood serum sample utilizing the electrochemical stimulator-analyzer, calculating a charge transfer resistance (R.sub.CT) of the recorded EIS, and detecting a COVID-19 infection of the person based on the calculated R.sub.CT if the calculated R.sub.CT is equal to or more than a threshold value.

Described herein are diagnostic and control fusion protein reagents and methods for use thereof in simple rapid and inexpensive hemagglutinin assays for the detection of subject antibodies directed to the SARS-CoV-2 virus.

The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.